HAG预激方案治疗中高危骨髓增生异常综合征的临床研究

摘要

Objective:To observe the efficacy of HAG regimen combined with homoharringtonine,low-dose cytarabine and granulocyte colony-stimulating factor on patients of intermediate and high-risk myelodysplastic syndrome.Methods:The clinical data of 16 new-diagnosed MDS cases treated with HAG regimen and 12 MDS cases treated with CAG regimen in our hospital from 2008 Jan to 2012 Feb were retrospectively analyzed.Results:The efficiency rate of HAG regimen was 87.50％ (14/16),CR rate 56.25％ (9/16).The efficiency rate of CAG regimen was 91.67％ (11/12)while the CR rate was 50％ (6/12).The CR rate and RR rate between HAG and CAG regimen didn t have statistically significant differences(P ＞ 0.05).Conclusion:With acceptable adverse effect,HAG regimen is effective for the intermediate and high-risk myelodysplastic syndrome,but strong and alternative chemotherapy is necessary for CR patients to keep longer CR and survival.%目的:观察高三尖杉酯碱、小剂量阿糖胞苷以及粒细胞集落刺激因子组成的HAG预激方案在中高危骨髓增生异常综合征患者中的疗效.方法:回顾性分析我院从2008年1月至2012年2月收治的16例HAG方案化疗及12例CAG方案化疗的初诊MDS患者的临床资料.结果:HAG方案诱导缓解的有效率为87.50％ (14/16),其中完全缓解率为56.25％ (9/16).CAG方案诱导缓解的有效率为91.67％ (11/12),其中完全缓解率为50％ (6/12).两组之间完全缓解率及总有效率比较无统计学差异(P＞0.05).结论:HAG方案治疗中高危MDS患者安全有效,取得CR后应继续巩固强化治疗,避免早期复发.